TY - JOUR
TI - Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems
AU - Constantinides, V.C.
AU - Paraskevas, G.P.
AU - Boufidou, F.
AU - Bourbouli, M.
AU - Stefanis, L.
AU - Kapaki, E.
JO - Parkinsonism and Related Disorders
PY - 2021
VL - 82
TODO - null
SP - 44-49
PB - Elsevier Ireland Ltd
SN - 1353-8020
TODO - 10.1016/j.parkreldis.2020.11.016
TODO - amyloid beta protein[1-42];  tau protein;  amyloid beta protein;  amyloid beta-protein (1-42);  biological marker;  peptide fragment;  tau protein, aged;  Article;  cerebrospinal fluid level;  clinical article;  clinical feature;  cohort analysis;  corticobasal degeneration;  disease association;  female;  human;  male;  nuclear magnetic resonance imaging;  phenotype;  priority journal;  risk factor;  Alzheimer disease;  cerebrospinal fluid;  extrapyramidal syndrome;  middle aged;  neurologic examination;  practice guideline;  predictive value;  retrospective study, Aged;  Alzheimer Disease;  Amyloid beta-Peptides;  Basal Ganglia Diseases;  Biomarkers;  Diagnostic Techniques, Neurological;  Female;  Humans;  Male;  Middle Aged;  Peptide Fragments;  Practice Guidelines as Topic;  Predictive Value of Tests;  Retrospective Studies;  tau Proteins
TODO - Introduction: Total tau (τT), phosphorylated tau (τP-181) and amyloid beta (Aβ42) are cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD). There is no consensus on the interpretation criteria of these biomarkers. The aim of this study was to apply three different sets of criteria for CSF AD biomarker interpretation in a cohort of corticobasal degeneration (CBD) patients. Method: SForty patients fulfilling diagnostic criteria for “probable CBD” were included. The AT(N), BIOMARKAPD/ABSI and the τP-181/Aβ42 ratio criteria were applied. Results: The AT(N) criteria categorized 50% of “probable CBD” patients as AD, and 62.5% as harboring amyloid pathology. The BIOMARKAPD/ABSI and τP- 181/Aβ42 criteria categorized ~40% of “probable CBD” patients as AD. Discussion: Use of different interpretation criteria for CSF AD biomarkers produces diverse results. AD pathology is common in patients fulfilling “probable” CBD criteria. CBD diagnostic criteria may have suboptimal positive predictive value. A consensus regarding interpretation criteria of CSF AD biomarkers is pivotal. © 2020
ER -